Anti-telomerase cancer therapy: CHOP/GADD153 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 6/July/2017, 7.14 am

Molecular therapy for brain tumor and oesophageal squamous cell carcinoma: Metformin, the widely used drug in the treatment of TIIDM, inhibit the expression of Integrin a7 (ITGA7), impair laminin-induced/FAK mediated signalling, inhibit the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppress tumor cell migration, reduce metastasis and prolong survival via down regulation of its target gene, 6/July/2017, 6.58 am
July 6, 2017
Low frequency magnetic field-based anti-metastatic therapy for CyclinD3-CDK6 overexpressing cancers: Low frequency magnetic field increases the levels of tumor suppressor proteins, inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 6/July/2017, 7.21 am
July 6, 2017
Show all

IntroductionWhat they say:  

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 issue of the Nature journal (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.


What we say

In connection with this finding,  Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports, for the first time, that: Anti-telomerase cancer therapy: CHOP/GADD153  suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene


Significance of the study:

Given that: (1) over 90% human tumors overexpress immortality gene telomerase; and (2) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to inhibit telomerase activity in human tumors; (ii) a way to increase the efficacy of anticancer therapy;  (iii) a cheapealternative to the existing expensive drugs(iv) a side-effect-free natural product-based drug; (v) a way to effectively treat cancers that are resistant to anticancer drugs;  (vi) a way to prevent tumor recurrence; and (vii) a way to effectively treat and eradicate metastatic progression of cancer.


From Research Findings to Therapeutic opportunity:

This study suggests that CHOP/GADD153by regulating the expression of its downstream target genes (fig. 1), it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1) and Telomerase (Fig 1)Remarkably, over 90% of the human tumors overexpress the cellular immortality gene telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy.

Figure 1. Mechanistic insights into CHOP/GADD153 functions as an anti-telomerase agent.

 

Taken together, pharmacological formulations encompassing   “CHOP/GADD153 activators, either alone or in combination with other anticancer drugs may be considered to treat human cancers that specifically overexpress the cellular immortality gene telomerase. 

price-100

[easy_payment currency=”USD”]


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How CHOP/GADD153 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and telomerase?
For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

CitationBoominathan, L., Anti-telomerase cancer therapy: CHOP/GADD153 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 6/July/2017, 7.14 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.